Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients

Therapeutic Drug Monitoring

Volumn 33, Issue 5, 2011, Pages 632-643

  Streit, Frank ^a   Binder, Lutz ^a   Hafke, Angelika ^a   Brandhorst, Gunnar ^a   Braulke, Friederike ^b   Haase, Detlef ^b   Armbrust, Thomas ^b   Cameron, Silke ^b   Ramadori, Giuliano ^b   Oellerich, Michael ^a   Walson, Philip ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

CML and GIST; imatinib; kinase inhibitors; monitoring; N desmethyl imatinib; unbound

Indexed keywords

DRUG METABOLITE; ERLOTINIB; IMATINIB; N DESMETHYL IMATINIB; NILOTINIB; OROSOMUCOID; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG DETERMINATION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TEACHING HOSPITAL; TREATMENT RESPONSE; ULTRAFILTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 80053562375     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182263ac4     Document Type: Article

References (36)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464. (Pubitemid 37211061)
2. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003;40:4-10.
3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480. (Pubitemid 34879334)
4. Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004; 103:2879-2891. (Pubitemid 38451655)
5. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23:9359-9368.
6. Larson RA, Druker BJ, Guilhot FA, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-4028.
7. Cortes JE, Egorin MJ, Guilhot F, et al. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. 2009;23:1537-1544.
8. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496-3499. (Pubitemid 46572540)
9. Singh N, Kumar L, Meena R, et al. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol. 2009;65:545-549.
10. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141-3147.
11. Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and role of alpha-1-acid glycoprotein. Br J Clin Pharmacol. 2006;62:97-112. (Pubitemid 44195246)
12. Gibbons J, Egorin MJ, Ramanatha RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008;26: 570-576. (Pubitemid 351264350)
13. Zandvliet AS, Schellens JH, Beijnen JH, et al. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clin Pharmacokinet. 2008;47:487-513. (Pubitemid 351969825)
14. Haouala A, Zanolari B, Rochat B, et al. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1982-1996.
15. De Francia S, D'Avolio A, De Martino F, et al. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1721-1726.
16. Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther. 2008;8:1387-1398.
17. Sawyers CL. Even better kinase inhibitors for chronic myeloid leukemia. N Engl J Med. 2010;363:2314-2315.
18. Hwang JE, Yoon JY, Bae WK, et al. Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor. BMC Cancer. 2010;10:438.
19. Baccarani M, Dreyling M. Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20S:105-107.
20. Smith PF, Bullock JM, Booker BM, et al. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy. 2004;24:1508-1514.
21. White DL, Sanders VA, Dang P, et al. OCT-1 mediated influx is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108:697-704.
22. Gurney H, Wong M, Balleine RL, et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther. 2007;82: 33-40. (Pubitemid 46944197)
23. Davies A, Hayes AK, Knight K, et al. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk Res. 2010; 34:702-707.
24. Widmer N, Decosterd LA, Leyvraz S, et al. Relationship of imatinib free plasma levels and target genotype with efficacy and tolerability. Br J Cancer. 2008;98:1633-1640. (Pubitemid 351684684)
25. Widmer N. Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia. Leuk Res. 2010;34:G98-G99.
26. I-COME: Imatinib COncentration Monitoring Evaluation: the clinical usefulness of "routine" versus "rescue" therapeutic drug monitoring (TDM) interventions in chronic myeloid leukaemia (CML) patients. 2009. Available at: http://www.controlled-trials.com/ISRCTN31181395. Accessed December 8, 2009.
27. Streit F, Shipkova M, Armstrong VW, et al. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem. 2004;50:152-159. (Pubitemid 38125712)
28. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatographytandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus and cyclosporine A in whole blood, Clin Chem. 2002;48:955-958. (Pubitemid 34587603)
29. Fayet A, Berguin A, de Tejada BM, et al. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit. 2008;30: 511-522.
30. Debaldo C, Chatelut E, Re M, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumours. Clin Cancer Res. 2006;12:6073-6078. (Pubitemid 44703771)
31. Kretz O, Weiss HM, Schumacher MM, et al. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, dog, monkey, healthy humans and patients with acute myelogenous leukemia. Br J Clin Pharmacol. 2004;58:212-216. (Pubitemid 39044003)
32. Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program. 2009:477-487
33. Blasdel C, Egorin MJ, Lagattuta, Druker BJ, et al. Therapeutic drug monitoring in CML patients on imatinib. Blood. 2007;110:1699-1701. (Pubitemid 47443991)
34. Petain A, Kattygnarath D, Azard J, et al on behalf of the Innovative Therapies with Children with Cancer European consortium. Population pharmacokinetics of imatinib in children and adults. Clin Cancer Res. 2008;14:7104-7109.
35. Li-Wang-Po A, Farndon P, Craddock C, et al. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. Eur J Clin Pharmacol. 2010;66:369-374.
36. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. a-1 Acid glycoprotein binds to imatinib (ST1571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res. 2003;9:625-632. (Pubitemid 36182594)